Alnylam Pharmaceuticals, Inc. (ALNY) shareholders
Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (12.80%) | 16,834,095 | 12.80% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (9.50%) | 12,675,053 | 9.50% | 13G (passive) amendment | Sep 30, 2026 |
| Capital World Investors | 10,916,799 | 8.20% | 13G (passive) amendment | Mar 31, 2026 |
| Capital Research Global Investors | 9,471,181 | 7.10% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 8,546,557 | 6.80% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 7,104,536 | 5.35% | 13G (passive) | Mar 31, 2026 |
| Vanguard Portfolio Management | 6,732,082 | 5.03% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALNY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 15,023,962 | 11.22% | $4.52B | +444,796 | 0.20% |
| Capital World Investors | 11,144,846 | 8.32% | $3.35B | +342,498 | 0.40% |
| BlackRock, Inc. | 10,907,675 | 8.14% | $3.28B | +462,767 | 0.05% |
| Capital Research Global Investors | 9,750,699 | 7.28% | $2.94B | +279,518 | 0.41% |
| Vanguard Portfolio Management LLC | 6,538,390 | 4.88% | $1.97B | +47,110 | 0.09% |
| Vanguard Capital Management LLC | 6,029,478 | 4.50% | $1.82B | +82,772 | 0.04% |
| T. Rowe Price Investment Management, Inc. | 5,642,173 | 4.21% | $1.70B | +448,849 | 1.11% |
| Invesco Ltd. | 3,754,318 | 2.80% | $1.13B | −320,802 | 0.09% |
| State Street Corp | 3,555,689 | 2.65% | $1.07B | +232,991 | 0.03% |
| JPMorgan Chase & Co | 2,675,517 | 2.00% | $785.32M | −3,648,235 | 0.04% |
| Geode Capital Management, LLC | 2,635,840 | 1.97% | $791.35M | −24,545 | 0.04% |
| Baillie Gifford & Co | 2,439,889 | 1.82% | $734.48M | −53,977 | 0.67% |
| Norges Bank | 2,271,813 | 1.70% | $683.88M | New | 0.07% |
| Wellington Management Group Llp | 2,110,407 | 1.58% | $635.30M | +174,482 | 0.11% |
| Orbis Allan Gray Ltd | 1,987,407 | 1.48% | $598.27M | +652,582 | 2.06% |
| Dodge & Cox | 1,955,393 | 1.46% | $588.63M | +26,140 | 0.31% |
| Two Sigma Investments, LP | 1,875,937 | 1.40% | $564.71M | −116,640 | 0.41% |
| American Century Companies Inc | 1,853,956 | 1.38% | $558.10M | +51,593 | 0.25% |
| Clearbridge Investments, LLC | 1,259,483 | 0.94% | $379.14M | −96,553 | 0.31% |
| Price T Rowe Associates Inc /Md/ | 1,149,201 | 0.86% | $345.95M | −283,547 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 788 | 133M | 99.7% | 87 / 324 | 280 / 80 | 12M | 9M |
| Q1 2026 | 793 | 131M | 98.1% | 106 / 320 | 261 / 156 | 30M | 19M |
| Q4 2025 | 852 | 134M | 100.0% | 172 / 289 | 292 / 117 | 15M | 15M |
| Q3 2025 | 823 | 134M | 100.0% | 225 / 283 | 223 / 49 | 20M | 18M |
| Q2 2025 | 654 | 133M | 99.0% | 98 / 261 | 216 / 63 | 10M | 7M |
| Q1 2025 | 625 | 129M | 96.7% | 106 / 235 | 205 / 67 | 10M | 8M |
| Q4 2024 | 594 | 128M | 95.5% | 98 / 239 | 180 / 62 | 13M | 11M |
| Q3 2024 | 568 | 126M | 94.1% | 107 / 221 | 171 / 57 | 22M | 9M |
| Q2 2024 | 523 | 122M | 90.9% | 88 / 193 | 168 / 57 | 12M | 8M |
| Q1 2024 | 498 | 118M | 88.0% | 71 / 205 | 150 / 64 | 10M | 13M |
| Q4 2023 | 499 | 121M | 90.4% | 96 / 168 | 159 / 44 | 9M | 6M |
| Q3 2023 | 453 | 118M | 88.0% | 43 / 161 | 166 / 59 | 5M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
705 funds held ALNY in Q2 2026, 28% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ALNY | Value | % of fund | As of |
|---|---|---|---|---|---|
| Growth Fund of America | 7,670,994 | 5.73% | $2.32B | 0.64% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 4,239,087 | 3.16% | $1.28B | 0.06% | Jun 30, 2026 |
| AMCAP Fund | 4,101,680 | 3.06% | $1.24B | 1.27% | May 31, 2026 |
| Vanguard Mid-Cap Index Fund | 2,893,030 | 2.16% | $870.89M | 0.39% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 2,834,095 | 2.12% | $853.15M | 0.17% | Jun 30, 2026 |
| Fidelity OTC Portfolio | 2,140,824 | 1.60% | $439.98M | 1.02% | Jul 31, 2026 |
| Vanguard Health Care Fund | 2,136,580 | 1.60% | $439.11M | 1.15% | Jul 31, 2026 |
| T. Rowe Price Capital Appreciation Fund | 2,034,761 | 1.52% | $612.52M | 0.87% | Jun 30, 2026 |
| Vanguard Growth Index Fund | 1,624,001 | 1.21% | $488.87M | 0.13% | Jun 30, 2026 |
| Investment Co of America | 1,612,942 | 1.20% | $485.54M | 0.26% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,530,865 | 1.14% | $460.84M | 0.47% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 1,338,874 | 1.00% | $404.31M | 0.41% | May 31, 2026 |
| Dodge & Cox Stock Fund | 1,233,200 | 0.92% | $371.23M | 0.31% | Jun 30, 2026 |
| Growth Fund | 1,197,876 | 0.89% | $360.60M | 0.63% | Jun 30, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1,165,773 | 0.87% | $350.93M | 1.52% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Yvonne Greenstreet | Chief Executive Officer, Director | 85,209 | 0.06% | Nov 17, 2026 |
| Bryan Supran | EVP, CLO and Secretary | 12,807 | 0.01% | Oct 6, 2026 |
| Melissa McLaughlin | Chief Human Resources Officer | 11,673 | 0.01% | Apr 7, 2026 |
| Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | 21,106 | 0.02% | Mar 6, 2026 |
| Jeffrey V. Poulton | EVP, Chief Financial Officer | 63,194 | 0.05% | Mar 6, 2026 |
| Tolga Tanguler | EVP, Chief Commercial Officer | 34,297 | 0.03% | Mar 6, 2026 |
| Pushkal Garg | EVP Chief R&D | 21,124 | 0.02% | Mar 6, 2026 |
| Robert W. Hesslein | EVP, CLO and Secretary | 8,002 | 0.01% | Mar 5, 2025 |
| David E. I. Pyott | Director | 33,262 | 0.02% | Nov 12, 2026 |
| Charles Elliott Sigal | Director | 5,046 | 0.00% | Nov 12, 2026 |
| Amy W. Schulman | Director | 25,959 | 0.02% | Nov 12, 2026 |
| Benjamin Cravatt | Director | – | – | Jun 3, 2026 |
| Colleen F. Reitan | Director | 1,446 | 0.00% | May 22, 2026 |
| Peter N. Kellogg | Director | 1,446 | 0.00% | May 22, 2026 |
| Margaret A. Hamburg | Director | 1,582 | 0.00% | May 22, 2026 |
| Olivier Brandicourt | Director | 1,446 | 0.00% | May 22, 2026 |
| Stuart A. Arbuckle | Director | 671 | 0.00% | May 22, 2026 |
| Dennis A. Ausiello | Director | 5,082 | 0.00% | May 22, 2026 |
| Michael W. Bonney | Director | 32,054 | 0.02% | Aug 19, 2025 |
| Carolyn R. Bertozzi | Director | 775 | 0.00% | May 12, 2025 |
| Phillip A. Sharp | Director | 278,149 | 0.21% | Jan 24, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yvonne Greenstreet Chief Executive Officer, Director | Nov 13, 2026 | Gift | −11,000 | – | – | 84,802 |
| David E. I. Pyott Director | Nov 10, 2026 | Option exercise | +3,780 | $71.99 | $272.12K | 5,362 |
| Charles Elliott Sigal Director | Nov 10, 2026 | Buy | +1,600 | $152.25 | $243.60K | 3,600 |
| Amy W. Schulman Director | Nov 9, 2026 | Buy | +1,910 | $156.82 | $299.53K | 25,959 |
| Bryan Supran EVP, CLO and Secretary | Oct 2, 2026 | Sale | −1,758 | $226.88 | $398.86K | 12,807 |
| Yvonne Greenstreet Chief Executive Officer, Director | Sep 19, 2026 | Award | +107 | – | – | 95,802 |
| David E. I. Pyott Director | Jun 1, 2026 | Sale(10b5-1 plan) | −1,222 | $299.87 | $366.44K | 2,094 |
| David E. I. Pyott Director | Jun 1, 2026 | Option exercise | +3,830 | – | – | 5,412 |
| David E. I. Pyott Director | Jun 1, 2026 | Sale(10b5-1 plan) | −495 | $300.72 | $148.86K | 1,599 |
| David E. I. Pyott Director | Jun 1, 2026 | Sale(10b5-1 plan) | −921 | $297.71 | $274.19K | 4,491 |
| David E. I. Pyott Director | Jun 1, 2026 | Sale(10b5-1 plan) | −17 | $302.65 | $5.15K | 1,582 |
| David E. I. Pyott Director | Jun 1, 2026 | Sale(10b5-1 plan) | −1,175 | $298.91 | $351.22K | 3,316 |
| David E. I. Pyott Director | May 20, 2026 | Award | +671 | – | – | 1,582 |
| Dennis A. Ausiello Director | May 20, 2026 | Award | +671 | – | – | 1,582 |
| Charles Elliott Sigal Director | May 20, 2026 | Award | +671 | – | – | 1,446 |
| Peter N. Kellogg Director | May 20, 2026 | Award | +671 | – | – | 1,446 |
| Colleen F. Reitan Director | May 20, 2026 | Award | +671 | – | – | 1,446 |
| Olivier Brandicourt Director | May 20, 2026 | Award | +671 | – | – | 1,446 |
| Amy W. Schulman Director | May 20, 2026 | Award | +838 | – | – | 24,049 |
| Stuart A. Arbuckle Director | May 20, 2026 | Award | +671 | – | – | 671 |
| Margaret A. Hamburg Director | May 20, 2026 | Award | +671 | – | – | 1,582 |
| Amy W. Schulman Director | May 13, 2026 | Option exercise | +11,250 | $70.20 | $789.75K | 23,211 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −56 | $320.14 | $17.93K | 11,673 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −909 | $329.76 | $299.75K | 10,764 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −829 | $330.46 | $273.95K | 9,935 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −293 | $331.89 | $97.24K | 9,642 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −199 | $333.94 | $66.45K | 9,443 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −147 | $320.62 | $47.13K | 12,287 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −245 | $322.86 | $79.10K | 11,818 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −224 | $321.64 | $72.05K | 12,063 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −86 | $319.69 | $27.49K | 12,434 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −81 | $323.64 | $26.21K | 11,737 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −8 | $325.49 | $2.60K | 11,729 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −359 | $317.44 | $113.96K | 12,729 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −265 | $316.61 | $83.90K | 13,088 |
| Melissa McLaughlin Chief Human Resources Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −209 | $318.47 | $66.56K | 12,520 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 5, 2026 | Sale(10b5-1 plan) | −153 | $326.24 | $49.91K | 20,569 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 5, 2026 | Sale(10b5-1 plan) | −148 | $324.60 | $48.04K | 20,722 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 5, 2026 | Sale(10b5-1 plan) | −233 | $323.25 | $75.32K | 20,870 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 5, 2026 | Sale(10b5-1 plan) | −124 | $321.81 | $39.90K | 21,103 |
| Pushkal Garg EVP Chief R&D | Mar 5, 2026 | Sale(10b5-1 plan) | −654 | $322.33 | $210.80K | 20,443 |
| Pushkal Garg EVP Chief R&D | Mar 5, 2026 | Sale(10b5-1 plan) | −740 | $323.55 | $239.43K | 19,703 |
| Pushkal Garg EVP Chief R&D | Mar 5, 2026 | Sale(10b5-1 plan) | −510 | $324.59 | $165.54K | 19,193 |
| Pushkal Garg EVP Chief R&D | Mar 5, 2026 | Sale(10b5-1 plan) | −500 | $326.08 | $163.04K | 18,693 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −59 | $320.81 | $18.93K | 21,744 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −79 | $321.82 | $25.42K | 21,665 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −28 | $320.01 | $8.96K | 21,803 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −57 | $325.67 | $18.56K | 21,227 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −75 | $324.88 | $24.37K | 21,284 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −210 | $323.84 | $68.01K | 21,359 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −96 | $323.01 | $31.01K | 21,569 |
| Kevin Joseph Fitzgerald CSO & EVP, Head of Research | Mar 4, 2026 | Sale(10b5-1 plan) | −29 | $319.03 | $9.25K | 21,831 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −374 | $323.01 | $120.81K | 63,137 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −309 | $321.82 | $99.44K | 63,511 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −230 | $320.81 | $73.79K | 63,820 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −291 | $324.88 | $94.54K | 62,028 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −818 | $323.84 | $264.90K | 62,319 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −223 | $325.67 | $72.62K | 61,805 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −109 | $320.01 | $34.88K | 64,050 |
| Jeffrey V. Poulton EVP, Chief Financial Officer | Mar 4, 2026 | Sale | −114 | $319.03 | $36.37K | 64,159 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Alnylam Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,379 shares on Sep 22, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Bryan Supran Officer | Oct 2, 2026 | 1,758 | $398.86K | Oct 2, 2026 | Restricted Stock Vesting |
| David E. I. Pyott Director | Jun 1, 2026 | 3,830 | $1.15M | Jun 1, 2026 | Exercise of stock options |
| Melissa McLaughlin Officer | Apr 6, 2026 | 2,286 | $731.75K | Apr 6, 2026 | Stock Award |
| Pushkal Garg Officer | Mar 5, 2026 | 2,404 | $778.15K | Mar 5, 2026 | RSU |
| Kevin Joseph Fitzgerald Officer | Mar 5, 2026 | 658 | $212.99K | Mar 5, 2026 | RSU |
| Kevin Joseph Fitzgerald Officer | Mar 3, 2026 | 1,652 | $530.90K | Mar 3, 2026 | RSU |
| Pushkal Garg Officer | Mar 3, 2026 | 1,775 | $570.43K | Mar 3, 2026 | RSU |
| Pushkal Garg Officer | Feb 27, 2026 | 4,627 | $1.53M | Feb 27, 2026 | PSU |
| Kevin Joseph Fitzgerald Officer | Feb 17, 2026 | 2,041 | $677.53K | Feb 17, 2026 | PSU |
| Kevin Joseph Fitzgerald Officer | Jan 13, 2026 | 2,290 | $845.24K | Jan 13, 2026 | PSU |
| Kevin Joseph Fitzgerald Officer | Nov 17, 2025 | 12,128 | $5.45M | Nov 17, 2025 | Exercise of stock options |
| Yvonne Greenstreet Officer, Director | Nov 12, 2025 | 25,650 | $11.62M | Nov 12, 2025 | Exercise of stock options |
| Pushkal Garg Officer | Oct 3, 2025 | 3,022 | $1.36M | Oct 3, 2025 | PSU |
| Colleen F. Reitan Director | Sep 9, 2025 | 18,000 | $8.30M | Sep 9, 2025 | Exercise of stock options |
| Tolga Tanguler Officer | Aug 29, 2025 | 3,474 | $1.57M | Aug 29, 2025 | PSU |
Congress trades
13 trades in Alnylam Pharmaceuticals reported by 5 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Jefferson Shreve IN06 | Sold | May 12, 2025 | $15K–50K | Jun 22, 2025 |
| Josh Gottheimer NJ05 · joint account | Sold | Jan 29, 2024 | $1K–15K | Feb 15, 2024 |
| Josh Gottheimer NJ05 · joint account | Bought | Jan 11, 2024 | $1K–15K | Feb 15, 2024 |
| Josh Gottheimer NJ05 · joint account | Sold | Dec 11, 2023 | $1K–15K | Jan 7, 2024 |
| Daniel Goldman NY10 | Bought | Mar 6, 2023 | $15K–50K | Apr 17, 2023 |
| Daniel Goldman NY10 | Sold | Jan 31, 2023 | $15K | Feb 24, 2023 |
| Josh Gottheimer NJ05 · joint account | Bought | Sep 28, 2022 | $1K–15K | Oct 16, 2022 |
| Barbara J Honorable Comstock VA10 | Sold | Mar 5, 2018 | $15K–50K | Mar 19, 2018 |
| Barbara J Honorable Comstock VA10 | Bought | Oct 12, 2017 | $15K–50K | Oct 13, 2017 |
| Richard L. Hanna NY22 | Bought | Dec 30, 2016 | $50K–100K | Jan 18, 2017 |
| Richard L. Hanna NY22 | Sold | Dec 30, 2016 | $1K–15K | Jan 18, 2017 |
| Richard L. Hanna NY22 | Sold | Dec 13, 2016 | $100K–250K | Jan 18, 2017 |
| Richard L. Hanna NY22 | Bought | Oct 13, 2016 | $100K–250K | Nov 27, 2016 |
See a number that looks wrong?